{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:02:02Z","timestamp":1744430522764,"version":"3.40.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tillotts Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy data on treatment in older adults are scarce, while the greatest increase in ulcerative colitis (UC) prevalence is observed in age groups of individuals 40 to 65 years of age and \u226565 years of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We assessed the difference in rates of clinical and endoscopic response and remission in UC adults (\u226460 years) and older adults (&amp;gt;60 years) treated with mesalazine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a post hoc analysis of data from a phase 3 noninferiority trial of 817 UC patients treated with mesalazine for 8 and additional 26 weeks in a double-blind and open-label study, respectively. We used Wilcoxon rank sum or chi-square test to analyze differences between groups and multivariable logistic regression to determine the associations between endoscopic remission as outcome (Mayo endoscopic subscore [MES]\u2005=\u20050 or\u2005\u22641) and independent variables including disease duration, baseline MES, age, sex, comedications, and comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Older adults had a longer disease duration, a higher number of comorbidities, concomitant medications, and higher baseline MES (2.38\u2005\u00b1\u20050.486 in older adults vs 2.26\u2005\u00b1\u20050.439 in adults; P = .008) compared with adults. We observed no difference in rates of combined clinical and endoscopic remission, clinical remission and response, and endoscopic remission and response at week 8 and 38 post-treatment. In addition to other well-known predictors of worse outcome, patients with\u2005\u22653 comedications were less likely to achieve an MES\u2005=\u20050 at week 8 and 38 and an MES\u2005\u22641 at week 38.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We observed similar efficacy of mesalazine in adult and older adult UC patients. The increased comedication number rather than age may decrease effectiveness of UC medications, highlighting the importance of healthy aging.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae123","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:40:10Z","timestamp":1718955610000},"page":"975-982","source":"Crossref","is-referenced-by-count":0,"title":["Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-7750","authenticated-orcid":false,"given":"Ekaterina","family":"Safroneeva","sequence":"first","affiliation":[{"name":"Tillotts Pharma AG , Rheinfelden ,","place":["Switzerland"]},{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-4623","authenticated-orcid":false,"given":"Helen","family":"Thorne","sequence":"additional","affiliation":[{"name":"Tillotts Pharma AG , Rheinfelden ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ortrud","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Tillotts Pharma AG , Rheinfelden ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Laoun","sequence":"additional","affiliation":[{"name":"Tillotts Pharma AG , Rheinfelden ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"6","key":"2025041105230743700_CIT0001","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2022.07.062","article-title":"The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study","volume":"163","author":"Agrawal","year":"2022","journal-title":"Gastroenterology."},{"issue":"Suppl 1","key":"2025041105230743700_CIT0002","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000503099","article-title":"Management of the elderly inflammatory bowel disease patient","volume":"101","author":"Hruz","year":"2020","journal-title":"Digestion."},{"issue":"1","key":"2025041105230743700_CIT0003","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025041105230743700_CIT0004","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/apt.13276","article-title":"Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy","volume":"42","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2025041105230743700_CIT0005","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025041105230743700_CIT0006","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cgh.2020.04.070","article-title":"Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials","volume":"19","author":"Cheng","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2025041105230743700_CIT0007","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","article-title":"Efficacy and safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease patients stratified by age","volume":"34","author":"Yajnik","year":"2017","journal-title":"Adv Ther."},{"issue":"5","key":"2025041105230743700_CIT0008","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ibd\/izab163","article-title":"Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"28","author":"Khan","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025041105230743700_CIT0009","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1038\/s41598-022-09455-8","article-title":"Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease","volume":"12","author":"Amano","year":"2022","journal-title":"Sci Rep."},{"issue":"8","key":"2025041105230743700_CIT0010","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","article-title":"Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients","volume":"14","author":"de Jong M","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025041105230743700_CIT0011","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/apt.16923","article-title":"Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study","volume":"56","author":"Pugliese","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2025041105230743700_CIT0012","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.15214","article-title":"Early combined immunosuppression may be effective and safe in older patients with Crohn\u2019s disease: post hoc analysis of REACT","volume":"49","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2025041105230743700_CIT0013","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/S2666-7568(22)00060-5","article-title":"Is it time to include older adults in inflammatory bowel disease trials? A call for action","volume":"3","author":"Vieujean","year":"2022","journal-title":"Lancet Healthy Longev"},{"year":"2022","author":"World Health Organization. Ageing and Health","key":"2025041105230743700_CIT0014"},{"issue":"3","key":"2025041105230743700_CIT0015","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/apt.14164","article-title":"Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis","volume":"46","author":"D\u2019Haens","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2025041105230743700_CIT0016"},{"issue":"8","key":"2025041105230743700_CIT0017","doi-asserted-by":"publisher","first-page":"CD000543","DOI":"10.1002\/14651858.CD000543.pub5","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"2025041105230743700_CIT0018","doi-asserted-by":"publisher","first-page":"CD000544","DOI":"10.1002\/14651858.CD000544.pub5","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"138","key":"2025041105230743700_CIT0019","first-page":"1286","article-title":"Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis","volume":"2010","author":"Sandborn","year":"1296","journal-title":"Gastroenterology."},{"issue":"9","key":"2025041105230743700_CIT0020","doi-asserted-by":"publisher","first-page":"701","DOI":"10.18553\/jmcp.2012.18.9.701","article-title":"Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis","volume":"18","author":"Yen","year":"2012","journal-title":"J Manag Care Pharm."},{"issue":"2","key":"2025041105230743700_CIT0021","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5455\/msm.2016.28.129-132","article-title":"Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies","volume":"28","author":"Zelko","year":"2016","journal-title":"Mater Sociomed."},{"issue":"2","key":"2025041105230743700_CIT0022","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2018.08.006","article-title":"Methods for measuring multiple medication adherence: a systematic review-report of the ISPOR Medication Adherence and Persistence Special Interest Group Value Health","volume":"22","author":"Pednekar","year":"2019","journal-title":"Value Health."},{"issue":"1","key":"2025041105230743700_CIT0023","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","article-title":"A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity","volume":"9","author":"Gellad","year":"2011","journal-title":"Am J Geriatr Pharmacother."},{"issue":"2","key":"2025041105230743700_CIT0024","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrgastro.2013.241","article-title":"Clinical implications of ageing for the management of IBD","volume":"11","author":"Ha","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"2025041105230743700_CIT0025","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5217\/ir.2019.00050","article-title":"Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study","volume":"17","author":"Wang","year":"2019","journal-title":"Intest Res"},{"key":"2025041105230743700_CIT0026","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.12659\/MSM.890567","article-title":"Efficacy of long-term 4.0 g\/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis","volume":"20","author":"Takeshima","year":"2014","journal-title":"Med Sci Monit."},{"key":"2025041105230743700_CIT0027"},{"issue":"2","key":"2025041105230743700_CIT0028","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology."},{"issue":"4","key":"2025041105230743700_CIT0029","doi-asserted-by":"publisher","first-page":"e100069","DOI":"10.1136\/gpsych-2019-100069","article-title":"Post hoc power analysis: is it an informative and meaningful analysis","volume":"32","author":"Zhang","year":"2019","journal-title":"Gen Psychiatr"},{"issue":"3","key":"2025041105230743700_CIT0030","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ecco-jcc\/jjw188","article-title":"European Crohn\u2019s and Colitis Organisation topical review on IBD in the elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025041105230743700_CIT0031","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ibd\/izab052","article-title":"Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases","volume":"27","author":"Kochar","year":"2021","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae123\/58292653\/izae123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/975\/58292653\/izae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/975\/58292653\/izae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:23:11Z","timestamp":1744348991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/4\/975\/7696862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,21]]},"published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae123","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,6,21]]}}}